Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and Exercise

Investigational Site Number 1560001, Beijing

Investigational Site Number 1560003, Beijing

Investigational Site Number 1560004, Beijing

Investigational Site Number 1560002, Beijing

Investigational Site Number 1560007, Changchun

Investigational Site Number 1560008, Changchun

Investigational Site Number 1560029, Harbin

Investigational Site Number 1560017, Shanghai

Investigational Site Number 1560023, Xuzhou

Investigational Site Number 1560014, Huai'an

Investigational Site Number 1560034, Qingdao

Investigational Site Number 1560026, Qingdao

Investigational Site Number 1560005, Tianjin

Investigational Site Number 1560013, Pingxiang

Investigational Site Number 1560024, Chongqing

Investigational Site Number 1560015, Zhuzhou

Investigational Site Number 1560035, Wuhan

Investigational Site Number 1560022, Guangzhou

Investigational Site Number 1560033, Guangzhou

Investigational Site Number 1560028, Yinchuan

Investigational Site Number 1560021, Guangzhou

Investigational Site Number 1560019, Huzhou

Investigational Site Number 1560025, Jining

Investigational Site Number 1560027, Jining

Investigational Site Number 1560012, Luoyang

Investigational Site Number 1560016, Shanghai

Investigational Site Number 1560006, Shijiazhuang

Investigational Site Number 1560009, Hohhot

Investigational Site Number 1560032, Yuncheng